EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

March 15, 2024

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 70 min

Earnings Call Speaker Segments

Nicola Fiore

operator
#1

Good afternoon, everyone, and welcome to the conference call on EL.En.'s financial results for Fiscal Year 2023. This call is being recorded, so there will be a chance to ask questions at the end of it. Joining me are Andrea Cangioli, EL.En.'s CEO, and Enrico Romagnoli, EL.En.'s Chief Financial Officer and Investor Relator. Before we start, please be aware that management will make remarks on this call regarding future expectations, trends and prospects, and forward-looking statements. Some statements on this call — including those addressing the company's beliefs, plans, objectives, estimates or expectations of possible future results or events — are forward-looking statements. Such statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry in which the company operates, and they may be affected if the underlying assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from those expressed or implied by any such forward-looking statement. The company assumes no obligation regarding the contents, nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof. <<operator_script>> At this point, I turn the floor over to Andrea Cangioli.

Nicola Fiore

operator
#2

Andrea, go right ahead.

Andrea Cangioli

executive
#3

Thank you, Nicola. Thanks to Bianca for organizing this call, and I appreciate all of you joining us today. This call comes on the heels of the draft 2023 financial report's release and the 2024 guidance — and with me are Andrea Cangioli and Enrico Romagnoli, who will walk through the financial portion of the report. 2023 proved to be a rather difficult year, yet the EL.En. Group was able to confront the conditions that have made our operating environment less favorable, all while keeping our revenue growth trends intact and holding the drop in profitability within the guidance we gave during the year. For a 14th consecutive year, the group posted a year-over-year rise in sales volume. This year, revenues ultimately grew by 2.8% -- 2.7%. We're highly pleased with that result, which puts average revenue growth over the last 3 years at roughly 10%. Consolidated revenues came in at about EUR 692 million, up approximately 3% versus 2022, and EBIT was around EUR 73 million, equal to 10.5% on revenues. During the fourth quarter of 2023, sales volume hit a record just under EUR 200 million, and the EBIT margin was likewise 10.5%.

Andrea Cangioli

executive
#4

On the FX side, currency movements added to revenue — had 2022’s exchange rates held, 2023 revenue would have gone past the EUR 700 million mark. Enrico will walk you through the specifics of certain cost accounting, showing how nonrecurrent and nonmonetary expenses affected our Q4 and full-year financial results. For now, let me share that excluding the nonrecurring expenses, our financials would have looked considerably stronger in the fourth quarter and for the year, and net of stock-based nonmonetary expense, the EBIT margin gap between ’22 and ’23 — 2022 and 2023 — would have been notably smaller. In fact, 2023 has been very positive for most of our business units. Our net business got off to a very strong start to the year, benefiting from the momentum of the strong 2022 order intake, and managed the normalization of market demand by progressively reducing its growth compared to 2022. Eventually, registering a volume decrease in fourth quarter — in the fourth quarter. At the same time, since the order intake normalization and sales volume reduction mainly involved the hair removal, which is the most competitive and therefore lower margin barrier application segment, overall margins on sales improved over the year.

Andrea Cangioli

executive
#5

Surgical devices performed well, particularly in urology and ENT. We also did well in anti-aging skin treatments, where innovation in products brought meaningful enhancements to our range. Support for sales through marketing was both broad and costly. The period when travel was prohibited and sales and marketing spending went only toward virtual networking is behind us. We have now returned to the conventional way of doing things. Although the rise in the sales and marketing line of the P&L is clear, we feel quite good about how effective that spending has been in backing the success of our selling efforts, since it helps place the products and brands appropriately at the high end of our markets. As an illustration of how far our investments go: our three medical aesthetic brands and companies — Deka, Quanta System and Asclepion — were present at the World Dermatology Congress held in Singapore last July. Incidentally, Singapore is likely the costliest location for an event of that kind; on its own it required market investment exceeding EUR 0.5 million. The good news here is that a congress of this type happens once every 4 years. The industrial business achieved overall sales growth in line with the consolidated sales growth.

Andrea Cangioli

executive
#6

And that came in under what we had initially anticipated, which was mostly linked to the rebound that everyone expected out of the Chinese markets. What actually happened with the trajectory of the Chinese economy proved to be quite different. So rather than driving revenue growth, our business in China actually became the driver of lower profit for us in 2023. I'd like to save China for the end of my presentation and continue walking with you through the other business areas and talk about how they succeeded in 2023. Cutlite Penta, which is active in the sheet metal laser-cutting business in, let's say, the Western world markets, was able to weather the softness of the Italian market and post a year-over-year sales increase thanks to its expansion in international sales. In a year when most machine suppliers for manufacturing struggled, revenues rose 9.3% and EBIT rose 5.5%, notwithstanding the nonrecurring cost that hopefully will be reversed in 2024. Cutlite offers a product range that keeps its appeal in the market because of its cost effectiveness and also because of the breadth of the product range. Ranging from compact low-cost but high-performance systems to complex systems with extended Cutlite surface, combined with handling and storing automations.

Andrea Cangioli

executive
#7

Lasit, which is active in identifying markets for laser marketing, is benefiting from a favorable market and from the long-term investment planning that began with the acquisition of the new large production plant, and it is now moving forward by creating a network of distribution subsidiaries aimed at better controlling the market and better serving the end user in the most significant international markets. Subsidiaries were set up in Poland, Spain, Germany and the U.K. And the good news here is that after the startup period, with the needed investment and subsequent losses, we are seeing a transition to profit generation at these new entities as well. We are talking about a business unit that won't be able to exceed EUR 30 million in size in 2024, so it's not a game changer for the group, but it is an interesting business, carrying EBIT margins well in excess of the sheet-metal market. The other businesses within the industrial sector performed fairly well given the economic environment of the year, basically confirming the financial results of 2022. We are talking about the marketing systems for decoration of large surfaces, the sale of mid-power CO2 laser sources and the sales of innovative marketing systems for selected applications in the manufacturing world, ranging from solutions to the so-called hairpin stripping for the wider defined market of electric vehicles to new approaches to the packaging markets.

Andrea Cangioli

executive
#8

Sustainability work carried on across the group, and those efforts also counted among the performance metrics tied to management compensation. We rolled out a fresh 5 years sustainability plan, aimed at climate change through cutting emissions, advancing the circular economy, encouraging a responsible supply chain, valuing people, and giving back to the community. That's a serious commitment, and it's gratifying to receive favorable responses to our -- to the broad effort we've made in lifting our ESG ratings from the leading rating agency, along with the awards we've been granted. Among the strongest financial developments in the second half of 2023 was the comeback of substantial cash generation, far exceeding the usual seasonal pattern that makes our fourth quarter the primary quarter for cash generation. We've explained to you how the 2022 supply tranche, driven by demand pressure of unmatched severity, pushed us into a series of emergency measures so we could keep our ability to fulfill the requested and projected delivery plans. Vendors received long-term purchase plans to guarantee product availability. Advanced payments were permitted to scale up and let vendors scale up their near-term delivery priorities, and purchasing volumes were adjusted in line with projected growth.

Andrea Cangioli

executive
#9

That move caused net working capital to climb quickly, driven by larger inventory stockpiles and reduced accounts payable. Once demand began returning to normal during the opening months of 2023, we also adjusted our purchasing practices, and the surplus inventory needed a while before it started working down gradually—something now entirely implemented, with clear gains for our cash position. One important element of our financial position is still trailing in its return to where it stood a couple of years back. I mean the customer down payment accounts. A reduction of EUR 24 million across the year on its own accounts for the entire cash transaction recorded in financial year 2023. This fall in down payments made by customers mostly impacts the sheet-metal cutting business. It is striking the Italian operations of Cutlite Penta, where the tax cuts that had required prompt down payments no longer exist, so customers are going back to the original practices that do not anticipate meaningful down payments. And it hits the Chinese operations of Penta Laser just as much. There, the cause is directly the weaker demand and, in turn, backlogs carrying less in down payments.

Andrea Cangioli

executive
#10

Here's where we get into the China discussion — the biggest letdown of 2023. China didn't just fail to be the revenue and profit engine we were relying on; it also posted an 8% decline in sales and a negative EBIT of EUR 8.5 million. It was nearly the sole cause of the gap between the 2022 results and those delivered — sorry, between what we delivered in 2023 and what we achieved in 2022. On top of that, the sales decline came despite the extra volume from the KBS acquisition, which contributed roughly EUR 14 million in revenues during 2023. Our system's domestic market in China isn't expanding the way we anticipated. It's weighed down by what's evident in the Chinese economy and has turned highly competitive, given how many players are actively and aggressively pursuing every niche. We're growing our overseas sales volume so we can gain from both better margins and higher volumes. The fourth quarter of 2023 delivered solid results, a nice rebound from the year's negative trajectory, though still not enough to meaningfully lift the annual figures. As for the IPO application in Mainland China, we kept you updated all year on how the weak financial results made a successful filing unviable.

Andrea Cangioli

executive
#11

So throughout 2023, the leasing project ended up being put on hold. The reason was that we were waiting to see whether the counter measures taken in China would once again lay out growth and profitability prospects strong enough to back listing aspirations. Then, in the first week of 2024, it became impossible to move ahead with submitting an IPO application tied to the 2023 results. Because of that, the private equity funds that had put money into Penta Laser Zhejiang back in 2022 sent through the withdrawal request they were contractually entitled to make. Meetings are now taking place, and in those meetings the funds are weighing whether to extend how long they stay in the shareholding structure, considering the commitments and guarantees currently under negotiation. If the funds confirm their exit, that would mean the IPO process gets interrupted and we would need to find alternative solutions for the business unit. A second, more specific event happened in late February 2024, and it was a factor that affected our 2023 financials. A customer of Penta Laser Zhejiang started a lawsuit, claiming reimbursement plus damages concerning a fairly large and complex system that we custom manufactured for him. We intend to counter sue him for payment, but for the time being, given how early the dispute is and the uncertainties around the probability of succumbing.

Andrea Cangioli

executive
#12

To wrap up, regarding the 2023 financials, we chose as a matter of prudence to set aside a sum equivalent to EUR 25 million of renminbi, which works out to roughly EUR 3.5 million of expense in Q4 2023. As I said, we've observed some material improvement in how the business is performing in China. And following the cost reduction activities, the 2024 plan — in 2024, we intend to improve our business performance relative to 2023. This brings us to the subject of 2024 guidance, but I'll return to that after Enrico's report. Yet one final point before I hand over to Enrico: I'd like to say something about dividend distribution. Staying true to our rationale of distributing dividends proportionally to the income generated, the Board of Directors is proposing to the shareholders a distribution of a EUR 0.20 dividend, which is 10% lower than last year, just as EBIT and net profit were roughly 10% lower. Please, Enrico, go ahead with your section.

Enrico Romagnoli

executive
#13

Thank you, Andrea. Good morning, everyone. As I typically do, I'll share a few remarks on the financial results we published yesterday. In 2023, the group posted total turnover of EUR 692 million, an increase of 3% from the prior year. Within the medical sector, growth came in at roughly 3%, and the same held for the industrial sector, which had recovered from a 4.1% decline through the end of September 2023. The sales contribution split between the two sectors was unchanged from last year. Q4 saw a record turnover figure nearing the three shorter of EUR 200 million, marking a 5.3% rise over the fourth quarter of 2022, with an operating result of EUR 21 million. The strongest gains came from the cutting and marketing business, whereas the medical sector's performance revealed a pattern of gradual deceleration across the year. With the residual momentum from the large order acquisition of 2022 now exhausted, we found ourselves progressively facing less favorable market conditions—shaped by the uncertainty brought about by the wars in Ukraine and Palestine and by elevated interest rates, which do not encourage capital investment. For the year overall, gross margin reached EUR 261.4 million, a 4.7% increase from EUR 249.7 million last year.

Enrico Romagnoli

executive
#14

That gain came in above the sales test recovery in sales margin, which moved from EUR 37.1 million to EUR 37.8 million, and the improved margin stems mainly from the sales mix in the medical sector, whereas margin on sales in the industrial sector saw a slight decline. The industrial sector's margin is also affected by the nonrecurring cost of roughly EUR 3 million tied to damage from the November fluid in Italy and to an accrual for potential impairment and inventory value connected with the legal dispute in China, as Andrea already mentioned. Operating expenses rose, with the impact on sales going from EUR 8.4 million to EUR 8.6 million, and the chief drivers are sales and marketing expenses for the trade fair in Congress, covered in both the medical and the industrial sector. Staff cost went up by EUR 13 million, rising as an impact on sales from 14.6% to 16.1%. The cost for stock options and share-based payment to employees added to the cost increase. In 2023, that amount was EUR 3.5 million versus EUR 1.5 million in 2022. Total stock option expenses in 2023 were EUR 3.9 million versus EUR 1.6 million in 2022, since EUR 0.4 million relating to the BOD was booked in G&A expenses.

Enrico Romagnoli

executive
#15

Sales took a 0.6% hit in 2023, versus 0.2% in 2022. At December 23, the group's headcount stood at 2,082 employees, lower than the prior year. The reduction touches the Chinese companies, excluding the newly acquired KBF of Shenzhen, whose figures weren't part of the 2022 totals. Because we adapted the workforce to the market's current, differing needs, staff in China — leaving KBF aside — moved from 894 units at the close of '22 to 663 at the close of '23. New hires, on the other hand, were mainly at Asclepion in Germany and Quanta System in Samarate. EBITDA came in at EUR 90.9 million, a decline of 4.6% against the 95.3% of '22. And the impact in sales — on sales edged down 14.1% in '22, 13.1% in '23. Depreciation and provision costs rose, moving from EUR 14.2 million to EUR 18.1 million, while the impact on turnover moves from 2.1% to 2.6%. The legal dispute already mentioned for the Chinese company, with a customer in Q4. In Q4, we booked a risk accrual of EUR 1.6 million, which, together with a EUR 1.7 million inventory devaluation for the system involving the supply, still carried within our inventories, brings the cost allocated to the dispute in the fourth quarter to EUR 3.3 million.

Enrico Romagnoli

executive
#16

EBIT came in positive at EUR 72.7 million, lower than the EUR 81 million recorded as of December '22, with a 10.5% EBIT margin versus 12% a year earlier. As a reminder, in November '23, Cutlite Penta sustained widespread damage from the fluid that struck its plants. Damage to warehouse goods, to the system in progress, and to equipment meant we had to book roughly EUR 1.7 million in expenses. Should the claim be approved, insurance reimbursement and a state compensation will be recorded when collected. So in Q4, EBIT -- which comes on the next slide, took a hit from 1.7 million in expenses booked for the fluid, EUR 3.3 million related to the Chinese legal dispute, amounting to EUR 5 million in total nonrecurring costs. Beyond that, versus '22, in '23 annual EBIT was weighed down by a higher nonmonetary charge for stock-based compensation of EUR 2.3 million. Total nonrecurring expenses equaled 2.5% of Q4 revenues and 0.7% of the U.S. revenues, whereas the higher nonmonetary cost represented 0.4% of onward sales. What this means is that Q4 EBIT margin would have stood at 13% on a current basis, and the current annual EBIT margin would have been 11.2% rather than 10.5%. And half of the 0.8% points gap in EBIT margin between '22 and '23 stemmed from an increase in stock-based compensation expenses, and yearly income before taxes shows a positive balance of EUR 71.1 million, a decrease of 9.9%, with the group closing the '23 financial year with net income of EUR 48.2 million against EUR 55.1 million last year.

Enrico Romagnoli

executive
#17

For the period, turnover took a hit equal to 7%. Net income in '23 was dragged down by Chinese operations, which posted a net loss of EUR 6 million versus income of EUR 1.3 million last year. Turning to the balance sheet. We can see the net financial position posted a decrease of EUR 20.8 million over the year, moving from EUR 75 million at the close of '22 to EUR 54.6 million as of December 31. We'd also remind you that non current assets include a midterm liquidity investment of EUR 23.8 million, so that amount is excluded from the net financial position. Capital expenditure came in at EUR 13 million — a significant figure, but well under the prior year's average, when substantial investment was made to boost production capacity. If you look at cash flow in the second half of 2023, the group went back to generating cash from operational activities, with the net financial position improving by roughly EUR 45 million during that period, which reversed the cash absorption trend seen in the first half of the year. In the main cash absorption, on a yearly basis you can see net working capital of EUR 34 million, even though there is — and you can see this in the second picture — a reduction during the year.

Enrico Romagnoli

executive
#18

On the other receivables and payables side, EUR 25 million — those relate mainly to the down payment Andrea already mentioned, plus a dividend payment of EUR 90 million made in May. Now on the revenue breakdown by business: in medical, revenues came to EUR 392.4 million, up 2.7 percentage. That growth came from solid performance in surgical application systems along with after-sale services and consumables, which more than offset the decline in the aesthetic segment. Aesthetic — our largest segment, at a 58% share of total medical turnover — was down 5%, with sales of EUR 226 million, hit by weakness at some important accounts for our removal system. The fastest growth came in surgery, up 25%, with turnover of EUR 77.2 million versus EUR 61.9 million in the prior financial year 2022. Within surgical application, a urology system made up the biggest share of turnover and was also the fastest growing. Therapy also grew slightly, up 1%, and turnover in after services and consumables rose roughly 10%, with a really bad contribution from optical fibers for subject application.

Enrico Romagnoli

executive
#19

After-sales revenue makes up a meaningful and recurring portion of our business. Within the industrial sector, revenue rose by roughly EUR 2.9 million, reaching EUR 300 million, versus EUR 291.5 million during the same period a year earlier. A standout fourth quarter drove that result, coming in at plus 22% against Q4 '22, which was especially encouraging for sales in China for laser cutting — plus 58% in the quarter in euro terms and plus 71% in renminbi. That signals a market relaunch, though it did not keep Chinese activities from posting an 8.3% decline on our basis in euro, and 0% in renminbi, even with the KBF acquisition at the end of '22, which added organic growth of about EUR 50 million. At the average exchange rate, the renminbi devalued against today's euro, up 7.6% in 2023. The laser cutting sector kept expanding in Italy, Europe and the Western market, thanks to Cutlite Penta, plus 9.3%, and Cutlite in Brazil, plus 2.8%. And Cutlite Penta based its growth almost entirely on expansion into international markets, particularly those outside you. In the marketing applications segment, the activities of Lasit and its subsidiaries came through strongly in 2023, recording the best turnover growth at plus 27% along with improved profitability, plus 123% in EBIT.

Enrico Romagnoli

executive
#20

Lasit of Torre Annunziata and the operations it runs — including distribution branches across Poland, Spain, Germany, and the U.K. — turned in a very strong showing, with revenues above EUR 26.7 million. Ot-las, which also operates in the market sector, saw sales fall 48%. As a result, the market segment overall grew 22%. Likewise, all the other sources and activity largely handled by the industrial division of <<inaudible>> posted a solid result, up 33%. Beyond the growth in the installed base for laser systems, services, system rentals, and consultancy have played a leading role in art conservation, which helped drive the fast expansion of after-sales service revenues in the industrial sector — a segment that posted growth of roughly 15%, with revenues of EUR 20.4 million. Looking at geography, the sales trend by macro region for the two sectors confirms the strongest performance came in free markets for the medical sector. In the industrial sector, meanwhile, the excellent sales results in Europe stand in contrast to the slowdown in the rest of the world, caused by lower sales booked in the cutting sector by Chinese companies — minus 8%, a contained slowdown, thanks to the rapid sales development of the other group companies active in the industrial sector, especially Cutlite Penta.

Enrico Romagnoli

executive
#21

On a constant exchange rate basis, revenues from the industrial sector in the rest of the world would be going up. Andrea, please continue with the remainder of the presentation.

Andrea Cangioli

executive
#22

Yes. Thank you, Enrico. I'd like to confirm the midterm — the positive midterm outlook regarding growth in our markets, in both the medical and industrial sectors, as backed by multiple researchers out there, and although some particular findings from each of them can be debated, all of them point to expected average growth rates of roughly 10% for medical and slightly above 6% for laser industrial applications. What has to go hand in hand with those numbers is that demand fuels growth, but sufficient supply that spurs demand does so as well. That's the reason R&D efforts matter so much to us, and we dedicate a growing budget to guarantee we keep the capabilities and resources needed to constantly enhance the performance and effectiveness of our product lineup so we can compete effectively in these expanding markets. Over the course of 2023, demand pressure returned to normal, and the group went back to operating through the channels that have historically defined its business. Even though 2023 opened with a sharp rise driven by the momentum from a very strong 2022, sales results in this first month of 2024 have been aligning with the normalization trend seen in 2023.

Andrea Cangioli

executive
#23

However, the orders we've booked for the upcoming months have been encouraging so far, and they point toward an expectation that progress will speed up over the remainder of the year. That enabled us to issue guidance for revenue and EBIT growth for 2024. In light of how uncertain conditions in the global market are, we cannot share any further specifics today about how large that growth will be. Clearly, hitting the revenue and profitability targets we're presenting to you today also hinges on whether we can meet the plans set for the industrial sector in China, which has recently displayed a great deal of instability and unpredictability. That wraps up our prepared remarks. And so, Bianca, I think we can now begin the Q&A portion.

Bianca Fersini-Mastelloni

operator
#24

Giovanni Selvetti from Berenberg, you have the floor.

Giovanni Selvetti

analyst
#25

Hi everybody, is my voice coming through, Andrea, Enrico?

Bianca Fersini-Mastelloni

operator
#26

Yeah, we can do that.

Andrea Cangioli

executive
#27

Yeah, yeah — we can hear you.

Giovanni Selvetti

analyst
#28

To begin with, congratulations on this set of results—not easy given the circumstances. So I have a couple of questions, some broader and some more specific. I'll start with the broad ones. I mean, you were just mentioning that research seems to point to 10% growth in medical and 5% in industrial. So my question was really that, so how would you—in terms of, let's just say, division, what can we expect? So growth in both divisions. And what's the assumption for China for this year? And again on guidance, is it fair to assume that the aesthetic division is expected to grow in 2024 after the inflection, and how is Accure going to contribute on that? The second question is on China—very glad to see that China is recovering in Q4. And given the strong top line growth in Q4, is it fair to assume that in the last quarter, there was also a positive contributor at the EBIT level after 3 quarters of negative impact? And staying on China, from the press release, I struggled to understand whether the project of listing the IPO is definitely off the table, or it's off the table now because the private equities are actually going out.

Giovanni Selvetti

analyst
#29

On that point, could you say which one has confirmed they will remain and which will exit, and what that amounts to in moderate terms? I have two further questions that are very specific and very brief. If you would — looking at the P&L after 8 years of positive figures, the change in inventory of finished goods and work in progress was negative, with a large number in Q4. So please explain that if you can. And the second is more technical, concerning the accruals for the Penta lawsuit. That impact sits below EBITDA, and the explanation given is the weight of DNA on sales in Q4 being so high. And does it also raise the reserve for risk and charges on the balance sheet? And my very last one, I promise, concerns growth for Cutlite Penta: you say it is mainly due to expansion in the international market. Is that mainly the U.S., and who are you competing with there?

Andrea Cangioli

executive
#30

Giovanni, you'll get the final question from me. Enrico will handle the remaining ones. The other questions, shall we say, about numbers. So, the last question: growth is happening in the international market. For Cutlite Penta, growth in the United States matters a lot, yet that isn't the sole driver of growth. Europe, too, is contributing substantially to the growth. Enrico — regarding the accrual for the lawsuit, I received the answer. I have it. Your first question didn't come through to me. Enrico, I'm not sure whether you caught it?

Giovanni Selvetti

analyst
#31

Yes, I’m not sure whether you caught that—if not, I can say it again.

Enrico Romagnoli

executive
#32

No, I don't have it.

Giovanni Selvetti

analyst
#33

The first technical question, then, was about the reason for a sizable shift in finished goods inventory and work in progress during the year's final quarter. Looking at the P&L, 2023 marked the first year since 7 in which that figure came out negative.

Andrea Cangioli

executive
#34

Usually, sales run higher at the close of the year. We carried finished-product inventory, and we shipped it out during the fourth quarter. That's pretty typical.

Giovanni Selvetti

analyst
#35

Right, but it was also negative for the year. That’s the reason I asked.

Andrea Cangioli

executive
#36

The same thing likely applies to the year as well. We probably had high — what that means is that at the close of 2023, we didn't ship everything out, and more stayed in inventories than had been the case the year before. That's probably — I believe this is mainly why we're lighter on finished goods this year compared with last year. As for EBITDA, and how the accrual affects EBITDA and EBIT, Enrico can explain that to you.

Enrico Romagnoli

executive
#37

Yeah, the accruals in China affected gross margin, or RMB 130 million — that's more or less EUR 1.6 billion — plus EUR 1.7 million, and for RMB 12 million, so roughly EUR 1.5 million in accruals. So we made a provision for risk, and the RMB 12 million was recorded in accrual and profitable risk and depreciation. That sits below EBITDA, ahead of EBIT.

Andrea Cangioli

executive
#38

Looking back, China's fourth quarter was strong. In fact, it showed a very large loss because of that accrual, though it would have been a slight loss regardless. The problem is that we're shifting — we're working to move our revenue toward higher-margin bearing revenue outside of China. We're making that shift progressively, but the process is still ongoing. So at the moment, we're still struggling. The 2024 budget behind the China guidance anticipates revenue growth, but it does not anticipate a profit contribution to consolidated results. That's where things stand today. On the question of medical market growth, yes, you're right. We expect to get back to growth in aesthetics as well, helped by the anticipated recovery of certain large accounts that were rather slow in 2023 in hair removal, but we anticipate strong results somewhat above the board across all our medical applications, particularly once more in the skin tipping anti-aging application. So we aren't disclosing the details today. But of course, with growth plotted for 2024, medical and aesthetic are expected to grow. Accure is going — it's going not very fast. I wouldn't credit Accure with a significant share of the expected growth.

Andrea Cangioli

executive
#39

Quanta System — the company that makes that system — should expand again. However, Accure's growth isn't the primary factor propelling Quanta System's growth in 2024. Regarding the IPO, your question about the IPO, I tried to be as precise as possible in what I laid out about the IPO. Naturally, if the withdrawal request from the private equity funds were accepted or enforced, it would trigger a technical suspension of the IPO, because we had to bring the private equity funds on board in order to file for an IPO with a financial shareholding by local investors — should they exit, we wouldn't be in this position. So that would technically suspend the IPO. All of them requested to withdraw, and we're in discussions to see whether we can persuade them to keep believing in the plan. The key point is that we also need to be able to demonstrate to them a solid financial recovery that would underpin an IPO project. Right now, results are very weak, and on top of that, this loss isn't helping in that regard.

Bianca Fersini-Mastelloni

operator
#40

And now joining us is Carlo Maritano from Intermonte.

Carlo Maritano

analyst
#41

I've got two questions, and both of them concern cash generation. So this year, you brought CapEx down to roughly EUR 13 million. What should we be expecting over the next couple of years? Should we expect a normalization relative to the IDI level from the prior year? And the second one concerns net working capital. You've cut net working capital quite a lot over the last 2 quarters. I was wondering whether we should still expect a few more quarters of reduction, given the lag in net working capital efficiencies that we typically observe. So if you have to expect a first part of the year, we're still looking at fairly good and robust cash generation.

Andrea Cangioli

executive
#42

Let's start with CapEx. Capital expenditures sit well under last year's average, since right now we don't need to grow our production capacity — or at least not through very large investments. China, which had been one of the primary drivers of capacity investment, no longer requires additional capacity. Elsewhere in the world — here in Italy, in Florence — we have smaller projects under way, and we do have some investments. Lasit will keep spending on the new building. Penta will do the same. Still, I think the order of magnitude for CapEx investment in 2023 will be more or less confirmed in 2024. On cash generation and net working capital, there is a seasonal pattern that typically favors the fourth quarter as the strongest quarter — not just because we sell the most in the fourth quarter, but also because our planning is usually tied to year plans. And in the first quarters, we try to be richer, so to speak, we safer. So we buy more, and then we tend to divert — to cut back on purchasing in the second half, where purchasing was in excess. Because of this, I don't expect to see a strong net working capital reduction in the first quarter of 2024 like the one we saw in the last quarter.

Andrea Cangioli

executive
#43

Even so, I don’t anticipate a pattern that moves in the same direction as what we saw during 2023.

Carlo Maritano

analyst
#44

Just following up on the aesthetic business. You mentioned expecting growth in 2024. I'm wondering whether you anticipate a fairly weak start to the year, given how 2023 exited, with a strong recovery coming in the second half, perhaps also helped by interest rate decreases. So is that also a factor we should be watching in 2024?

Andrea Cangioli

executive
#45

Yes. I’ll confirm what I said earlier: compared with the strong start in 2023, we expect a weak start. It’s March 15, so we’re well into the first quarter of 2024. Given what we’re seeing in order bookings, we expect a progressive recovery. Throughout 2023, we saw what I call normalization — a slowdown from that huge order intake to normal volumes. At the start of 2024, we’ve seen an increase, good vitality, which leads us to expect solid revenue results beginning in the second quarter and beyond.

Bianca Fersini-Mastelloni

operator
#46

And now let's go to Andrea — Andrea Bonfa with Banca Akros is on the line. Andrea Bonfa, are you there?

Andrea Bonfà

analyst
#47

Yes. Sorry, you should be able to hear me now. Apologies for that. No, I really do apologize — my connection is quite bad — but anyway, most of what I wanted to ask has already been covered. Still, Andrea, I was hoping you could expand on your guidance, because you're counting on a recovery in medical, yet we got this minus 6% exit. So I'm wondering whether that's more due to our new product pipeline or, on the commercial side, these accounts that are supposed to recover. And could you perhaps say more about which geographical areas you expect that recovery to come from? The second thing is industrial laser: you already said you don't expect China to help profitability recover, but do you in any way expect industrial to contribute to your EBIT growth guidance?

Andrea Cangioli

executive
#48

Yes. Let's begin with the second question. Yes, you're correct. I did say that — in fact, I don't expect China to contribute to profitability, while I do expect China to contribute to the recovery in profitability. This meeting — that I don't expect big profits coming from China this year — I expect a strong reduction in the losses. Regarding medical, you are right. Our growth expectation, especially in aesthetic, is based on specific facts. The first and most important is a transverse effect: we released an impressive set of new products and new improved products starting from the half of 2023. I'm talking, just to give an example, of the pro line of Deka, which started with the release of Asia Pro, own the Pro and <<inaudible>> in July and finished with the release of DataPro, Motus PRO and SmartSide Pro in the month of January 2024. So we are renewing the product range, and this is expected to stimulate our customers. Then we have important new products for our large OEM customers in the U.S. market that should hit the market in the first and second quarter — we are talking of new products for her removal and new products for body contouring.

Andrea Cangioli

executive
#49

There's a lot of anticipation, particularly around her removal, where we were weak all year long—also because certain large U.S.-based accounts performed slowly. Third, we're seeing a recovery in an area that had been extremely brilliant in 2022, which marked a slowdown for geopolitical reasons in 2023—we're talking about the Middle East, which is a very significant market for hair removal. We're seeing good recovery signs as of today for this specific market.

Bianca Fersini-Mastelloni

operator
#50

And now, Andrea, we've got Emilie Da Silva from Eiffel Investment on the line, and she has a question regarding China.

Emilie Da Silva

analyst
#51

Just a quick follow-up there on China. You mentioned the recovery you expect for 2024. I've got a question about the Q4 numbers in China. That recovery was driven mostly by volume. What about pricing in China as well? And what's your expectation when it comes to volumes — many new clients or new contracts — just to elaborate a bit more on the dynamics there? And what revenue level do you need to reach to be profitable there?

Andrea Cangioli

executive
#52

Thanks, Emilie, for that question. It isn't simple to respond, since we possess detailed plans showing volumes by area, price by area, and margin by area, all built on the margin we anticipate earning previously — though not in every case, let's say, because these plants have demonstrated reliability given how fast the market shifts. So what's certain today is that we are lowering the cost base. And so we went — our breakeven point sits much lower now. And so my view is that although the internal plans require a very large recovery, a quick recovery, I am more cautious, and I believe that slightly beating 2023 would be a good results in China this year. We expect the revenue mix to be much more weighted toward overseas, where we have higher margins, and we expect even lower margins in China currently. The whole mix would in any case be able, as I mentioned, also answering Andrea Bonfa's question, to strongly reduce the losses or also to see a profit for the end of the year.

Bianca Fersini-Mastelloni

operator
#53

Andrea, there's another question coming in from Giovanni Selvetti over at Berenberg.

Giovanni Selvetti

analyst
#54

Perhaps something regarding the market. A significant merger recently occurred in the industry involving Cynosure and Lutronic. Given that you've had a partnership with Cynosure historically as well, I was simply curious about the potential impact if revenues from Cynosure were to drop to zero.

Andrea Cangioli

executive
#55

That's a fair question. Cynosure was our company and our partner, so this shift matters quite a bit. As things stand, Cynosure purchases their high-end per removal device from us on an OEM basis. We already have orders booked for all of 2024, and Cynosure has shown no indication of trying to walk away from that commitment, which is a firm one. Looking to the midterm, Cynosure and Lutronic could develop an internal solution, since Lutronic is a very strong maker of high-end hair removal devices built around Alexandrite laser heads. The scale of sales volume to Cynosure — booked in 2023 and anticipated for 2024 — sits well under EUR 20 million, just to give a sense of magnitude. On the other hand, I'd like to point out that a merger between two big players naturally creates a very formidable competitor in the market, one that could pair distribution strength with technical strength. Yet on the flip side, as we've witnessed many times in the market, the combined company will face the challenge of managing two separate teams, and not all companies have succeeded in handling mergers of that kind.

Andrea Cangioli

executive
#56

Usually, the cost savings promised as justification for a board's merger decision fail to materialize. Beyond that, such deals push several professionals out of the market, since in a merger people get sacrificed—when, say, you pick one distribution setup in a given country over another, you must decide between going to market with company A's distribution or company B's. So our view is that although we face a big competitor, we'll still get a chance to deepen our presence in particular markets by capitalizing on whatever the merger leaves behind.

Bianca Fersini-Mastelloni

operator
#57

Andrea, our list doesn't contain any further questions, so I'd like to open up the floor and ask whether anyone else has a question. If not — if nothing more comes in — we'll bring this conference to a close. Should you have any questions you'd like to look into, please feel free to reach out to Enrico Romagnoli. He'll be glad to help with whatever you need. Thanks for joining this conference, and we look forward to having you all with us again next time. Good afternoon, everyone.

Andrea Cangioli

executive
#58

Thanks, everyone.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.